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Abstract
Purpose This study aims to compare the prevalence of poten-
tially inappropriate medicines (PIMs) and potential prescrib-
ing omissions (PPOs) using several screening tools in an Irish
community-dwelling older cohort, to assess if the prevalence
changes over time and to determine factors associated with
any change.
Methods This is a prospective cohort study of participants
aged ≥65 years in The Irish Longitudinal Study on Ageing
(TILDA) with linked pharmacy claims data (n=2051). PIM
and PPO prevalence was measured in the year preceding par-
ticipants’ TILDA baseline interviews and in the year preceding
their follow-up interviews using the Screening Tool for Older
Persons’ Prescriptions (STOPP), Beers criteria (2012),
Assessing Care of Vulnerable Elders (ACOVE) indicators
and the Screening Tool to Alert doctors to Right Treatment
(START). Generalised estimating equations were used to de-
termine factors associated with change in prevalence over time.
Results Depending on the screening tool used, between
19.8 % (ACOVE indicators) and 52.7 % (STOPP) of partici-
pants received a PIM at baseline, and PPO prevalence ranged
from 38.2 % (START) to 44.8 % (ACOVE indicators), while
36.7 % of participants had both a PIM and PPO. Common
criteria were aspirin for primary prevention (19.6 %) and
omission of calcium/vitamin D in osteoporosis (14.7 %).
Prevalence of PIMs and PPOs increased at follow-up (PIMs
range 22–56.1 %, PPOs range 40.5–49.3 %), and this was
associated with patient age, female sex, and numbers of med-
icines and chronic conditions.
Conclusions Sub-optimal prescribing is common in older pa-
tients. Ongoing prescribing review to optimise care is impor-
tant, particularly as patients get older, receive more medicines
or develop more illnesses.
Keywords STOPP . START . Beers criteria . ACOVE
indicators . Cohort . Potentially inappropriate prescribing
Introduction
Medicines are the most common healthcare intervention
worldwide, and despite providing many benefits, they also
carry potential risks which can lead to patient harm [1].
Physiological changes in ageing which alter drug pharmaco-
dynamics and pharmacokinetics can predispose older people
to adverse drug events [2]. Additionally, older people are more
likely to be taking multiple medicines and have multiple med-
ical conditions, increasing the likelihood of drug-drug or
drug-disease interactions [2–4].
Due to concerns regarding appropriate medication use in
this age group, a number of screening tools/criteria have been
devised to define what constitutes potentially inappropriate
prescribing (PIP) in the elderly. PIP can be classified as either
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(i) potentially inappropriate medicines (PIMs), the use of a
medicine where no clear clinical indication exists or the use
of an indicated medicine in circumstances where the risks
outweigh the benefits, or (ii) potential prescribing omissions
(PPOs), not prescribing a beneficial medicine for which there
is a clear clinical indication [5].
Although PIP can be determined implicitly on the basis of
clinician’s judgement, the majority of research has determined
it explicitly using published criteria/screening tools, a large
number of which have been developed [5]. The earliest such
tool was Beers criteria, first published in 1991 as a list of drugs
to be avoided in older nursing home residents [6]. It contained
many medicines not commonly prescribed outside of the
USA, and updates to the Beers criteria include drugs which
are more widely used internationally and also drugs to avoid
with certain conditions [7]. Although earlier iterations of the
Beers criteria have been used extensively in the literature, the
2012 criteria have yet to be widely applied [8]. The Screening
Tool for Older Person’s Prescriptions (STOPP) and Screening
Tool to Alert doctors to Right Treatment (START) were de-
veloped as screening tools for PIMs and PPOs, respectively,
suitable for use in European countries and have been applied
and validated in the literature [9–12]. Outside of specific PIP
screening tools, the Assessing Care of Vulnerable Elders
(ACOVE) indicators were developed by the Research and
Development (RAND) Corporation to assess the overall qual-
ity of care of older people [13]. Several ACOVE indicators
relate to PIMs and PPOs, and these have been assessed for use
as a PIP screening tool and have good inter-rater reliability
[14, 15].
Much published literature on this topic has only focussed
on PIMs with few studies utilising PPO screening tools. Of
those studies that considered both PIMs and PPOs, none have
reported how these two forms of PIP overlap [16–21].
Additionally, little is known about how the prevalence of
PIMs and PPOs changes over time in older populations and
determinants of change. This study aims to (i) compare the
prevalence of potentially inappropriate prescribing (both
PIMs and PPOs) in a cohort of community-dwelling people
aged 65 years and older in Ireland according to a number of
screening tools and (ii) assess if the prevalence of potentially
inappropriate prescribing in this cohort changes over time and
to determine the factors associated with any change.
Methods
Study population
The population for this prospective cohort study comprised a
subset of participants in The Irish Longitudinal Study on
Ageing (TILDA) for whom medication dispensing history
was available. TILDA is a nationally representative cohort
study of more than 8000 community-dwelling people aged
50 years or over charting their health, social, and economic
circumstances (see Supplementary file 1 for details of
collected information). TILDA participants were deemed eli-
gible for this study if they were aged 65 years or older at
baseline and supplied a valid General Medical Services
(GMS) identifier to allow linkage of their medication dispens-
ing history from the Health Service Executive Primary Care
Reimbursement Service (HSE-PCRS) pharmacy claims data-
base. The HSE-PCRS GMS scheme provides free health ser-
vices to eligible persons in Ireland, including a wide range of
prescribed medicines, although a monthly co-payment per
prescription item has applied since October 2010. Eligibility
for the GMS scheme is based on means testing, although all
people aged over 70 were eligible until December 2008 when
a higher income threshold was introduced for this age group
compared to the general population.
Data collection
TILDA participant recruitment and wave 1 baseline data col-
lection were carried out between 2009 and 2011 when partic-
ipants were interviewed face to face, completed a question-
naire and underwent a health assessment. TILDA follow-up
waves are scheduled every 2 years, the first of which was
carried out from February 2011 to March 2012. Medication
data were extracted from the HSE-PCRS pharmacy claims
database on the basis of GMS identifier for each participant
in the present study for the 15 months preceding the date of
their TILDA baseline and follow-up interviews. The
HSE-PCRS database contains a GMS identifier, sex and date
of birth, drug information (World Health Organisation
Anatomical Therapeutic Chemical (ATC) code, strength, de-
fined daily dosage (DDD)), quantity dispensed and date of
dispensing. Linkage of participants’ TILDA and HSE-PCRS
dispensing data was carried out using methods published pre-
viously [22]. All data were anonymised after linkage was per-
formed. Ethical approval for TILDA was provided by the
Faculty of Health Sciences Ethics Committee at Trinity
College Dublin.
Potentially inappropriate prescribing criteria
The prevalence of PIP was measured during two time inter-
vals: in the 12 months preceding each participant’s baseline
TILDA interview and in the 12 months preceding their
follow-up interview. A longer period of time was analysed
for criteria dependent on duration of medication use of greater
than 1 month to allow for 12 months of potential exposure.
Dispensing data from the HSE-PCRS database and informa-
tion from TILDA on diagnoses, medications not included in
the HSE-PCRS database (self-reported) and other characteris-
tics were used to assess if participants had received a PIM or
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had a PPO. Participants were classified as having a PIM if they
were prescribed the potentially inappropriate medicine at any
time during the study periods, while having a PPO was clas-
sified as not receiving the indicated medicine at any time
during the study periods.
A subset of criteria from STOPP, Beers criteria (2012) and
the third iteration of the ACOVE indicators were applied to
dispensing data and information from TILDA to measure
PIMs. Forty-five of 65 (69 %) STOPP criteria, 42 of 52
(81 %) Beers criteria and 17 of 22 (77 %) ACOVE indicators
relating to inappropriate medicines were used. To measure
PPOs, a subset of criteria from START and the ACOVE indi-
cators were used. Fifteen of 22 (68 %) START criteria were
applicable, while 21 of 65 (34 %) ACOVE indicators relating
to prescribing indicated that medicines could be applied. All
criteria for which the necessary participant information was
available in the HSE-PCRS pharmacy claim that database and
TILDAwere applied.
Statistical analysis
Prevalence estimates were calculated for each set of PIM and
PPO criteria as well as for each individual criterion.
Additionally, the prevalence of each criterion (where applica-
ble) as a proportion of the number of participants with the
condition/disease or prescribed the drug of interest was deter-
mined, for example, of those prescribed a benzodiazepine
during the study period, the proportion who were prescribed
it for >4 weeks. McNemar’s test for paired groups comparison
was used to test whether the prevalence of criteria changed
significantly between the two time periods. Generalised esti-
mating equations (GEE) with exchangeable correlations were
used to investigate determinants of the change in prevalence
of PIMs and PPOs [23]. Unadjusted analysis estimating
change in overall PIM and PPO prevalence from baseline to
follow-up was followed by multivariable GEE analysis which
adjusted for sex, age, numbers of regular medicines and diag-
nosed chronic conditions (reported at TILDA interview) at
baseline and follow-up in the models. Level of educational
attainment as an indicator of socio-economic status was
assessed for inclusion in the models. Analyses were per-
formed using SAS 9.2 (SAS Institute Inc., Cary, NC, USA)
and Stata version 12 (Stata Corporation, College Station, TX,
USA).
Results
Sample characteristics
This study included 2051 TILDA participants (Fig. 1), of
which 1107 (53.97 %) were female, and mean participant
age (SD) in this sample was 74.8 (6.2)years. Mean number
of reported regular medicines (SD) increased from 4.1 (2.9) at
baseline to 4.9 (3.2) at follow-up, while mean number of
chronic conditions reported (SD) was 2.4 (1.6) and 2.9 (1.7)
at TILDA baseline and follow-up interviews, respectively.
Fig. 1 Flow diagram of study
participants from TILDA cohort
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Prevalence of potentially inappropriate medicine use
and potential prescribing omissions
When assessed using STOPP, 1081 participants (52.7 %) were
prescribed a PIM during the baseline study period, while prev-
alence of Beers PIMs and ACOVE PIMs was significantly
lower (30.5 and 19.8 % respectively, p<0.05). The prevalence
of PPOs at baseline was 44.8 % when assessed using ACOVE
indicators and 38.2 % using START (see Table 1). Overall,
61.4 % of the sample had a PIM defined by any of the screen-
ing tools, 53.3 % had any PPO and 753 (36.7 %) participants
had both a PIM and PPO. A total of 2963 PIMs and 2315
PPOs were identified during this study period.
The most common (prevalence >2 %) individual PIM
criteria and PPO criteria are reported in Tables 2 and 3, re-
spectively. All applied criteria are presented in Supplementary
file 2. The most prevalent baseline PIM criteria were aspirin
with no history of coronary, cerebral or peripheral arterial
symptoms or occlusive arterial event (STOPP, 19.6 %) and
proton pump inhibitor (PPI) at full therapeutic dosage for
>8 weeks (STOPP, 17.2 %). The most prevalent baseline
PPO criteria were calcium and vitamin D supplement omis-
sion in patients with self-reported osteoporosis (ACOVE in-
dicators and START, 14.7 %) and omission of a laxative in an
older person with persistent pain treated with opioids
(ACOVE indicators, 11.0 %).
Change in prevalence over time
The prevalence of PIMs and PPOs increased significantly
(p<0.05) between the baseline and follow-up study periods
for each screening tool (Table 1). At follow-up, 64.8 % of
participants received a PIM, and 56.6 % received a PPO de-
fined by any of the screening tools, while the proportion of the
sample with both a PIM and PPO increased to 41.1 % (843
participants).
The prevalence of PIMs increased between waves and the
unadjusted odds ratio (OR) for the presence of any PIM, com-
paring follow-up to baseline, was 1.08 (95 % CI 1.03, 1.13),
using unadjusted GEE analysis. A multivariate GEE model
(Table 4) showed that female sex, age and higher number of
medicines were significantly associated with change in PIM
prevalence and the change in prevalence at follow-up com-
pared to baseline was not significant after adjusting for these
covariates. Similarly for PPO prevalence, the association for
follow-up compared to baseline in the unadjusted analysis
(OR 1.07, 95 % CI 1.02, 1.11) was no longer significant in
the multivariable model (Table 4), where age and higher num-
bers of medicines and chronic conditions were found to be
significantly associated with change in PPO prevalence.
When included, level of education was not significant in the
models and adjusting for it did not alter any of the other odds
ratios.
The most common PIM and PPO criteria (prevalence
>2 %) during the follow-up period are presented in Tables 2
and 3, respectively. A number of individual criteria showed
highly significant (p<0.0001) increases in prevalence be-
tween baseline and follow-up, including prescription of PPIs
at full therapeutic dosage for >8 weeks (STOPP, 17.2 to
21.9 %). Only prescription of long-term (>1 month)
long-acting benzodiazepines (STOPP/ACOVE, 3.9 to
3.1 %) and omission of antihypertensives in participants with
elevated blood pressure (START, 5.5 to 3.5 %) significantly
decreased in prevalence.
Discussion
Statement of principal findings
This study showed in a cohort of 2051 community-dwelling
people aged 65 and over, more than 61 % received a PIM in a
1-year period defined by a subset of STOPP criteria, Beers
criteria and ACOVE indicators, while 53 % had a PPO
Table 1 Number of participants with PIMs and PPOs at baseline
and 2-year follow-up
Screening tool Baseline Follow-up
N % (95 % CI) N % (95 % CI)
STOPP 1080 52.7 (50.5, 54.8) 1151 56.1 (54.0, 58.3)
1 611 29.8 (27.8, 31.8) 602 29.4 (27.4, 31.3)
2 270 13.2 (11.7, 14.6) 307 15.0 (13.4, 16.5)
≥3 200 9.8 (8.5, 11.0) 242 11.8 (10.4, 13.2)
Beers criteria 625 30.5 (28.5, 32.5) 678 33.1 (31.0, 35.1)
1 325 15.8 (14.3, 17.4) 349 17.0 (15.4, 18.6)
2 192 9.4 (8.1, 10.6) 203 9.9 (8.6, 11.2)
≥3 108 5.3 (4.3, 6.2) 126 6.1 (5.1, 7.2)
ACOVE indicators 407 19.8 (18.1, 21.6) 451 22.0 (20.2, 23.8)
1 336 16.4 (14.8, 18.0) 372 18.1 (16.5, 19.8)
2 62 3.0 (2.3, 3.8) 63 3.1 (2.3, 3.8)
≥3 9 0.4 (0.2, 0.7) 16 0.8 (0.4, 1.2)
Any above PIMa 1259 61.4 (59.3, 63.5) 1330 64.8 (62.8, 66.9)
START 783 38.2 (36.1, 40.3) 831 40.5 (38.4, 42.6)
1 551 26.9 (24.9, 28.8) 586 28.6 (26.6, 30.5)
2 171 8.3 (7.1, 9.5) 171 8.3 (7.1, 9.5)
≥3 61 3.0 (2.2, 3.7) 74 3.6 (2.8, 4.4)
ACOVE indicators 918 44.8 (42.6, 46.9) 1011 49.3 (47.1, 51.5)
1 465 22.7 (20.9, 24.5) 494 24.1 (22.2, 25.9)
2 279 13.6 (12.1, 15.1) 331 16.1 (14.5, 17.7)
≥3 174 8.5 (7.3, 9.7) 186 9.1 (7.8, 10.3)
Any above PPOa 1094 53.3 (51.2, 55.5) 1161 56.6 (54.5, 58.8)
a PIM and PPO screening tools are not mutually exclusive, overall prev-
alence of PIMs and PPOs accounts for any overlap
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Table 2 Prevalence of individual PIM criteria (prevalence ≥2 %) at baseline and 2-year follow-up
Criteria description Baseline Follow-up
n % of
sample
% of
indicationa
n % of
sample
% of
indicationa
Change in
prevalence
(95 % CI)
STOPP
Cardiovascular system
Loop diuretic for dependent ankle oedema only 97 4.7 – 114 5.6 – 0.8 (−0.6, 2.2)
Aspirin with history of PUD without H2 receptor antagonist or PPI 40 2.0 71.4 38 1.9 59.4 −0.1 (−0.9, 0.7)
Aspirin with no history of coronary, cerebral or peripheral arterial
symptoms or occlusive arterial event
402 19.6 – 377 18.4 – −1.2 (−3.9, 1.4)
Central nervous system
TCAs with an opiate or calcium channel blocker 46 2.2 – 69 3.4 – 1.1 (0.1, 2.1)**
Long-term (>1 month), long-acting benzodiazepines 80 3.9 34.8 64 3.1 33.0 −0.8 (−1.9, 0.4)*
Gastrointestinal System
PPI at full therapeutic dosage for >8 weeks 353 17.2 42.6 450 21.9 47.4 4.7 (2.0, 7.4)***
Musculoskeletal system
NSAID with history of PUD, unless with concurrent H2 receptor
antagonist, PPI or misoprostol
37 1.8 77.1 41 2.0 83.7 0.2 (−0.6, 1.0)
NSAID with moderate-severe hypertension >160/100 mmHgb 187 9.1 33.0 207 10.1 34.0 1.0 (−0.9, 2.9)
Long-term use of NSAID (>3 months) 99 4.8 14.2 107 5.2 16.2 0.4 (−1.0, 1.8)
Long-term corticosteroids (>3 months) as monotherapy for
rheumatoid arthrtitis/osteorarthritis
37 1.8 20.6 47 2.3 20.8 0.5 (−0.4, 1.4)
Drugs that adversely affect fallers
Benzodiazepines in those prone to falls 63 3.1 14.4 55 2.7 11.4 −0.4 (−1.4, 0.6)
Neuroleptic drugs in those prone to falls 34 1.7 7.8 49 2.4 10.2 0.7 (−0.1, 1.6)
Analgesic drugs
Regular opiates for >2 weeks without concurrent use of laxatives 109 5.3 90.8 103 5.0 84.4 −0.3 (−1.7, 1.1)
Duplicate drug classes
Any regular duplicate drug class prescription 51 2.5 – 66 3.2 – 0.7 (−0.3, 1.8)
Beers criteria (2012)
Anticholinergics
Antispasmodics 35 1.7 – 46 2.2 – 0.5 (−0.3, 1.4)
Central nervous system
Tertiary TCAs 97 4.7 – 119 5.8 – 1.1 (−0.3, 2.5)*
Benzodiazepines, short, intermediate and long acting 201 9.8 – 180 8.8 – −1.0 (−2.9,0.8)
Non-benzodiazepine (Z-drug) hypnotics, avoid chronic
use >90 days
48 2.3 17.3 56 2.7 17.4 0.4 (−0.6, 1.4)
Gastrointestinal
Metoclopramide 22 1.1 – 42 2.0 – 1.0 (0.2, 1.7)*
Pain
Non-COX-selective NSAIDs, avoid chronic use 93 4.5 12.1 81 3.9 10.6 −0.6 (−1.8, 0.7)
Drug-disease interactions
Avoid with history of falls/fractures (fracture and fall or>1
fall or >1 fracture) (total)
124 6.0 54.4 168 8.2 59.2 2.1 (0.5, 3.8)***
Anticonvulsants 20 1.0 8.8 46 2.2 16.2 1.3 (0.5, 2.0)***
Benzodiazepines 64 3.1 28.1 76 3.7 26.8 0.6 (−0.5, 1.7)
Z-drugs 42 2.0 18.4 60 2.9 21.1 0.9 (−0.1, 1.8)
SSRIs 40 2.0 17.5 45 2.2 15.8 0.2 (−0.6, 1.1)
ACOVE indicators
Falls and mobility problems
If ≥2 falls (or 1 fall with injury) in previous year discontinue
benzodiazepine
43 2.1 14.9 44 2.1 12.0 0.0 (−0.8, 0.9)
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defined by a subset of STARTcriteria and ACOVE indicators.
Aspirin for primary prevention, prolonged use of full thera-
peutic dosage PPIs and strong anticholinergic drugs were the
most common PIMs, while common omissions were calcium
and vitamin D in osteoporosis, laxatives for patients on opi-
oids and gastro-protection with an NSAID. The increase in
PIM and PPO prevalence between baseline and follow-up is
associated with patient characteristics (age, female sex, num-
bers of prescribed medicines and chronic conditions) rather
than being a function of time.
Results in the context of current literature
It is not surprising that the prevalence varies depending on the
screening tool used as each includes different types of pre-
scribing in what is classified as potentially inappropriate.
Also, the Beers criteria and ACOVE indicators were first de-
veloped for use in the USA, whereas STOPP and START are
more widely applicable. A number of studies have estimated
the prevalence of PIP using multiple screening tools.
Prevalence estimates have been highly variable as research
has been carried out across settings (hospitals, residential care,
community), in a number of countries and using data ranging
from full clinical records to administrative data meaning that
only a subset of PIP criteria have been applied [17].
A systematic review of studies applying the STOPP and/or
START criteria found prevalence ranging from 21 to 79 % for
PIMs and 22 to 74 % for PPOs [12]. PIM prevalence accord-
ing to the Beers criteria varied from 3 to 40 % in studies
included in a review of the 1991 Beers criteria, and up to
53.4 % using more recent iterations of Beers criteria [24,
25]. The ACOVE indicators have not been applied extensive-
ly, with two studies reporting the prevalence of ACOVE PPOs
giving estimates of 58 and 58.5 % [14, 26]. A previous study
of TILDA participants using STOPP/START reported lower
PIM and PPO prevalence at baseline interview than the cur-
rent study (14.6 and 30 %) [21]; however, fewer criteria were
applied and prevalence was measured at one time point rather
than over a period of 12 months.
A number of studies have assessed the prevalence of both
PIMs and PPOs; however, the present study appears to be the
first to report on the proportion of study participants with
concurrent PIMs and PPOs [16–21]. An association has been
demonstrated between polypharmacy (using≥five medica-
tions concomitantly) and underprescribing [27], so the high
rate of concurrent PIMs and PPOs is not unexpected.
Few epidemiological studies have reported the longitudinal
prevalence of PIP, and findings have shown a trend of PIP
decreasing over time [28, 29]. A cohort study which, like the
present study, controlled for numbers of prescribed medicines
and co-morbidities found that sub-optimal prescribing
remained unchanged or decreased over a 4-year follow-up
period after adjusting for these factors [30].
Clinical and policy implications
Potentially inappropriate prescribing in older people is a com-
mon issue and warrants attention to improve the quality of
Table 2 (continued)
Criteria description Baseline Follow-up
n % of
sample
% of
indicationa
n % of
sample
% of
indicationa
Change in
prevalence
(95 % CI)
Hypertension
If a vulnerable elder (VE) has HTN discontinue NSAID or COX-2
inhibitorb
79 3.9 7.8 80 3.9 7.1 0.0 (−1.2, 1.3)
Medication Use
Discontinue benzodiazepine if taking for >1 month 80 3.9 34.8 64 3.1 33.0 −0.8 (−1.9, 0.4)*
Avoid medication with strong anticholinergic effects 245 11.9 – 288 14.0 – 2.1 (−0.1, 4.3)**
In iron-deficiency anaemia, prescribe no more than one low-dose
oral iron tablet daily
27 1.3 20.1 43 2.1 30.3 0.8 (0.0, 1.6)
ACE angiotensin converting enzyme, COPD chronic obstructive pulmonary disease, COX cyclo-oxygenase, GI gastrointestinal,HTN hypertension,MI
myocardial infarction, NSAID non-steroidal anti-inflammatory drug, PPI proton pump inhibitor, PUD peptic ulcer disease, SSRI selective serotonin
reuptake inhibitor, TCA tricyclic antidepressant, TIA transient ischaemic attack, VE vulnerable elder
*McNemar’s test p<0.05
**McNemar’s test p<0.01
***McNemar’s test p<0.001
a Prevalence of PIM criteria as a proportion of all participants with the disease or prescribed the drug of interest e.g. prevalence of benzodiazepines for
>4 weeks as a proportion of all participants prescribed a benzodiazepine
bHypertension defined using objectively measured blood pressure or self-reported hypertension diagnosis with antihypertensive medication
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Table 3 Prevalence of individual PPO criteria (prevalence ≥2 %) at baseline and 2-year follow-up
Baseline Follow-up
Criteria description n % of
sample
% of
indicationa
n % of
sample
% of
indicationa
Change in prevalence
(95 % CI)
START
Cardiovascular system
Warfarin (or another oral anticoagulant) in
the presence of chronic atrial fibrillation
154 7.5 67.5 190 9.3 62.9 1.8 (0.1, 3.4)***
Aspirin/clopidogrel with a history of
atherosclerotic coronary, cerebral or
peripheral vascular disease
48 2.3 14.2 51 2.5 14.6 0.1 (−0.7, 1.0)
Antihypertensive therapy where systolic
blood pressure >160 mmHgb
77 5.5 31.3 49 3.5 19.6 −2.0 (−3.4, −0.6)***
Statin therapy with a history of coronary,
cerebral or peripheral vascular disease
67 3.3 20.7 82 4.0 21.8 0.7 (−0.3, 1.8)*
ACE inhibitor following acute MI 61 3.0 14.6 58 2.8 11.9 −0.1 (−1.0, 0.8)
β blocker with chronic stable angina 84 4.1 37.3 81 3.9 33.8 −0.1 (−1.2, 0.9)
Respiratory system
Regular inhaled β2 agonist or anticholinergic
agent for mild to moderate asthma or COPD
102 5.0 37.0 116 5.7 37.5 0.7 (−0.6, 2.0)
Musculoskeletal system
Bisphosphonates if taking oral corticosteroids
for >3 months
62 3.0 60.2 71 3.5 64.5 0.4 (−0.5, 1.4)
Calcium and vitamin D supplement with osteoporosis 301 14.7 57.9 329 16.0 51.6 1.4 (−0.9, 3.6)*
Endocrine system
Antiplatelet therapy in diabetes mellitus if ≥1
major CV risk factor (hypertension,
hypercholesterolaemia, smoking history)
56 2.7 27.6 64 3.1 28.6 0.4 (−0.5, 1.4)
Statin therapy in diabetes mellitus if ≥1 major CV
risk factor
50 2.4 24.6 50 2.4 22.3 1.4 (−0.9, 3.6)
ACOVE indicators
COPD
If a VE has COPD, prescribe a rapid-acting
bronchodilator
43 2.1 40.2 66 3.2 46.2 1.1 (0.3, 2.0)***
If a VE with COPD has 2+ exacerbations
requiring antibiotics/oral corticosteroids in the
previous year, then (in addition to a long-
acting bronchodilator) prescribe inhaled
steroids (if not taking oral steroids)
20 1.0 58.8 41 2.0 63.1 1.0 (0.4, 1.6)
Diabetes
If a VE with diabetes mellitus not on
anticoagulant or antiplatelet, then daily
aspirin should be prescribed
54 2.6 26.9 58 2.8 27.2 0.2 (−0.7, 1.1)
Hypertension
If a VE with HTN has IHD, prescribe a
β blockerc
62 3.0 37.1 63 3.1 34.6 0.0 (−0.9, 1.0)
If a VE with HTN has a history of HF, IHD,
chronic kidney disease or CVaccident,
prescribe an ACE inhibitor/ARBc
66 3.2 29.2 68 3.3 26.8 0.1 (−0.9, 1.1)
Ischaemic heart disease
If a VE has had an MI, prescribe a β blocker 61 3.0 34.5 59 2.9 30.3 −0.1 (−1.0, 0.8)
If a VE has IHD, prescribe an ACE inhibitor/
ARB
81 3.9 36.0 82 4.0 34.2 0.0 (−1.0, 1.1)
Medication use
If a VE with a risk factor for GI bleeding
(aged ≥75, PUD, warfarin use, chronic
glucocorticoid use) is prescribed a non-
selective NSAID, treat concomitantly
with misoprostol/a PPI
207 10.1 68.5 182 8.9 65.0 −1.2 (−3.0, 0.5)
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care provided to this age group. However, this complex prob-
lem may not be accurately captured using administrative data.
Participants may not have responded to first-line treatment or
have contraindications resulting in a PIM being prescribed or
an indicated medicine being omitted. Prescribers may have to
weigh up the incremental benefit of one additional indicated
medicine against increasing the treatment burden in older pa-
tients already takingmultiple medications. The structure of the
health system in Ireland, in particular the lack of implementa-
tion of a co-ordinated chronic disease management policy
across primary and secondary care, may also contribute to
the rate of PIP, and future implementation of this policy could
have a positive impact on prescribing [31].
The strength of evidence of inappropriateness varies across
criteria and the risk-benefit ratio may have changed since PIP
screening tools were developed. For example, aspirin for pri-
mary prevention is included in STOPP, but evidence is con-
flicting on the net benefit in people with cardiovascular risk
factors but without previous cardiovascular events/symptoms
[32, 33].
A high proportion of study participants have both prescrib-
ing errors of commission (PIMs) and omission (PPOs). This
Table 3 (continued)
Baseline Follow-up
Criteria description n % of
sample
% of
indicationa
n % of
sample
% of
indicationa
Change in prevalence
(95 % CI)
Osteoporosis
If a VE without osteoporosis is taking
≥7.5 mg/day of prednisone (or equivalent)
for ≥1 month, prescribe calcium and
vitamin D
53 2.6 59.6 53 2.6 57.6 0.0 (−0.8, 0.8)
If a VE has osteoporosis, prescribe calcium
and vitamin D supplements
301 14.7 57.9 329 16.0 51.6 1.4 (−0.9, 3.6)
If a female VE has osteoporosis, treat with
bisphosphonate, raloxifene, calcitonin,
HRT or teriparatide
186 9.1 48.9 249 12.1 53.2 3.1 (1.2, 4.9)***
If a male VE has osteoporosis, treat with
bisphosphonate, calcitonin, parathyroid
hormone or testosterone
123 6.0 87.9 144 7.0 85.2 1.0 (−0.4, 2.5)***
Pain
If a VE with persistent pain is treated with
opioids, prescribe a stool softener/laxative
225 11.0 82.7 265 12.9 82.0 2.0 (0.0, 3.9)*
Stroke
If a VE has had a TIA or stroke, prescribe
antiplatelet/anticoagulant therapy
83 4.0 58.9 99 4.8 54.4 0.8 (−0.4, 1.9)**
ACE angiotensin converting enzyme, ARB angiotensin II receptor blocker, COPD chronic obstructive pulmonary disease, COX cyclo-oxygenase, CV
cardiovascular,GI gastrointestinal,HF heart failure,HRT hormone replacement therapy,HTN hypertension, IHD ischaemic heart disease,MImyocardial
infarction, NSAID non-steroidal anti-inflammatory drug, PPI proton pump inhibitor, PUD peptic ulcer disease, TIA transient ischaemic attack, VE
vulnerable elder
*McNemar’s test p<0.05
**McNemar’s test p<0.01
***McNemar’s test p<0.001
a Prevalence of PPO criteria as a proportion of all participants with the disease or prescribed the drug of interest e.g. prevalence of ACE inhibitor omission
as a proportion of all participants who have had an acute MI
b Six hundred sixty-one participants (32.2 %) had missing data for measured blood pressure
c Hypertension defined using objectively measured blood pressure or self-reported hypertension diagnosis with antihypertensive medication
Table 4 Population-averaged GEE models for change in sample
prevalence of PIMs and PPOs
Adjusted odds ratio (95 % CI) (n=2046a)
Any PIM Any PPO
Follow-up (vs baseline) 1.00 (0.95, 1.06) 0.97(0.92, 1.02)
Age (years) 1.03 (1.02, 1.04)* 1.03 (1.02, 1.04)*
Female (vs male) 1.27 (1.07, 1.5)* 0.86 (0.72, 1.01)
Number of medicines 1.20 (1.17, 1.24)* 1.04 (1.01, 1.07)*
Number of chronic
conditions
1.05 (0.99, 1.11) 1.47 (1.39, 1.56)*
*z score p<0.05
a Self-reported number of medicines was missing at both time points for
five (0.2 %) participants
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suggests that reviewing both suitability of current medicines
and assessing the need for additional indicated therapies is
necessary to optimise prescribing for older people.
The long-term prescription of full therapeutic dosage PPIs
has been identified previously as a particularly common issue
in older people and represents a significant cost burden [34].
Though the cost-effective use of PPIs in Ireland has been
promoted through policies such as reference pricing and pre-
ferred drug schemes, a focus on prescribing appropriate dos-
ages and durations may provide clinical benefits to patients as
well as cost savings [35, 36]. Although long-term benzodiaz-
epine use declined in this study, this may be explained by
substitution with Z-drug hypnotics which showed a
non-significant increase in prevalence. Omission of antihyper-
tensive therapy also declined at follow-up, which may have
been due to participants with high blood pressure at baseline
interview being advised to discuss this with their general
practitioner.
Strengths and limitations of the study
This study’s participants are community-dwelling older peo-
ple from a nationally representative study on ageing, which
improves the generalisability of these findings. Although only
participants with eligibility to the means-tested GMS scheme
were included, a high proportion (73.5 %) of TILDA partici-
pants aged over 65 reported GMS eligibility (see Fig. 1).
The use of administrative pharmacy claims data in this
study may provide more accurate information on medication
exposure than self-reported medication use, although good
agreement has been found between such sources [22]. It also
allowsmedication exposure to be determined over a 12-month
time period to provide a more accurate assessment of PIM and
PPO prevalence, as opposed to using medication data from
one point in time which could underestimate PIMs and over-
estimate PPOs.
A limitation of pharmacy claims data is that patients may
not have actually consumed medications dispensed (i.e. if pa-
tients are non-adherent), and a lack of information on medi-
cines purchased over-the-counter may lead to an overestima-
tion of some prescribing omissions (e.g. calcium and vitamin
D, laxatives). Additionally, there may have been a clinical
reason why some participants had a PIM/PPO; however, as
no clinical notes were available, it is not possible to determine
clinicians’ rationale for such prescribing decisions.
A number of criteria from each of the PIM and PPO screen-
ing tools could not be included in this analysis due to the
required information not being available in the administrative
and survey data used. However, the combination of these data
sources allows for a greater number of criteria to be applied
than with either source alone [21]. Some information on diag-
noses was based on participants self-report and so may not
accurately reflect the presence/absence of the conditions of
interest.
Conclusions
Although prevalence of PIMs and PPOs can vary depending
on the screening tool used, such prescribing issues are com-
mon and may become more prevalent in patients with more
medicines or chronic illnesses. This underlines the importance
of ongoing prescribing review for older patients, both to assess
the appropriateness of current drug therapy as well as to eval-
uate the need for additional clinically indicated treatments.
Further research is planned to examine the association be-
tween potentially inappropriate prescribing over time and ad-
verse health outcomes.
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